A multicenter ring study was conducted to assess the assay performance of the HER2 Dual ISH application by The United Kingdom National External Quality Assessment Service for Immunocytochemistry (UK NEQAS
), and a high concordance rate between the bright-field and dark-field HER2 assays for diagnosing HER2 status was demonstrated.
Over the three year (2007-2009) review period, the laboratory routinely participated in two EQA programmes for anti-ENA detection, namely the rheumatic disease module from the Immunology RCPA (Australia) and the nuclear and related antigen module issued by UK NEQAS
Phe is procuring a digital microscope slide scanner for use in its colindale neqas
This is different than in the UK NEQAS
and NordicQC PT programs, which involve central review of slides stained for human epidermal growth factor receptor type 2 (HER2), estrogen receptor (ER), and progesterone receptor (PR).
is a national organisation of external quality assessment (EQA) programmes providing quality assessment in both primary and secondary care to centres performing pathology tests.
(1) Among many other elements, the guideline mandates include assay validation and revalidation with demonstration that "positive ER or PgR categories are 90% concordant and negative ER or PgR categories are 95% concordant" (in comparison with clinically validated assays), (1,25) as well as ongoing proficiency testing, at least twice a year, with satisfactory performance defined as "90% correct responses on graded challenges." (1) Proficiency testing data allow analysis of assay variables from large numbers of participant laboratories; in fact, the UK Neqas
program first drew attention to problematic (false positive) staining with the PgR rabbit monoclonal SP2.
Contract notice: Provision of Courier Services to UK NEQAS
for H&I Welsh Blood Service T252.
The laboratory participates in the external quality assurance program of the UK NEQAS
for Peptide Hormones (Edinburgh); laboratory biases were [less than or equal to] 2.5% (mean 0.4%) for 6 consecutive samples that had GH concentrations of 0.22-0.52 ng/mL, near the cutpoint of 0.4 ng/mL used for the GH suppression test.
(33.) UK NEQAS
ICC & ISH Immunocytochemistry Journals.
Technical aspects of predictive and prognostic markers in breast cancer: what UK NEQAS
(26.) UK NEQAS
annual report 2007: immunology, allergy and immunochemistry.
Web site: 2014; http://www.ukneqas.org.uk/content/Pageserver.asp.